Is the imbalance between pro-angiogenic and anti-angiogenic factors associated with preeclampsia?

Clinica Chimica Acta

Volumn 447, Issue , 2015, Pages 34-38

  Jardim, Letícia Lemos ^a   Rios, Danyelle Romana Alves ^b   Perucci, Luíza Oliveira ^a   de Sousa, Lirlândia Pires ^a   Gomes, Karina Braga ^a   Dusse, Luci Maria S ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO JOÃO DEL REI   (Brazil)

Author keywords

Angiogenesis; Endoglin; PlGF; Preeclampsia; SFlt 1; VEGF

Indexed keywords

ANGIOGENESIS MODULATOR; ANGIOGENIC FACTOR; ENDOGLIN; NICOTINE; PLACENTAL GROWTH FACTOR; PRAVASTATIN; VASCULOTROPIN; VASCULOTROPIN 121; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD ANALYSIS; BLOOD PRESSURE REGULATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE MARKER; DOWN REGULATION; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; GENE; GENE IDENTIFICATION; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC RISK; GESTATIONAL AGE; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; NONHUMAN; PATHOPHYSIOLOGY; PIGF GENE; PLACENTA DISORDER; PREDICTIVE VALUE; PREECLAMPSIA; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEINURIA; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SFLT 1 GENE; UPREGULATION; URINALYSIS; VASCULAR RESISTANCE; VEGF GENE; VEGFR1 GENE; ANIMAL; FEMALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PRE-ECLAMPSIA; PREGNANCY;

ANIMALS; BIOMARKERS; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PRE-ECLAMPSIA; PREGNANCY;

EID: 84929643653     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.05.004     Document Type: Review

References (50)

1. Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22.
2. American College of Obstetricians and Gynecologists; Task Force on hypertension in Pregnancy, Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on hypertension in pregnancy. Obstet Gynecol 2013, 122:1122-1131.
3. von Dadelszen P., Magee L.A., Roberts J.M. Subclassification of preeclampsia. Hypertens Pregnancy 2003, 22:143-148.
4. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003, 111(5):649-658.
5. Agarwal I., Karumanchi A. Preeclampsia and the anti-angiogenic state. Pregnancy Hypertens 2011, 1(1):17-21.
6. Moore Simas T.A., Crawford S.L., Solitro M.J., et al. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007, 197. [244.e1-8].
7. Hertig A., Liere P. New markers in preeclampsia. Clin Chim Acta 2010, 411(21-22):1591-1595.
8. Romero R., Nien J.K., Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble VEGF receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small-for-gestational-age neonate. J Matern Fetal Neonatal Med 2008, 21(1):9-23.
9. Cheng D., Hao Y., Zhou W., Ma Y. Vascular endothelial growth factor +936C/T, -634G/C, -2578C/A, and -1154G/A polymorphisms with risk of preeclampsia: a meta-analysis. PLoS One 2013, 8(11):e78173.
10. Shibuya M., Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 2006, 312(5):549-560.
11. Yamazaki Y., Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006, 10(4):515-527.
12. Maharaj A.S., Walshe T.E., Saint-Geniez M., et al. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med 2008, 205(2):491-501.
13. Tsatsaris V., Goffin F., Munaut C., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003, 88(11):5555-5563.
14. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004, 350:672-683.
15. Cerdeira A.S., Karumanchi S.A. Angiogenic proteins as aid in the diagnosis and prediction of preeclampsia. Scand J Clin Lab Invest 2010, 242:73-78.
16. Taché V., Lacoursiere D.Y., Saleemuddin A., et al. Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity. Hum Pathol 2011, 42(9):1283-1288.
17. Wikström A.K., Larsson A., Eriksson U.J., et al. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia. Obstet Gynecol 2007, 109:1368-1374.
18. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006, 355(10):992-1005.
19. Furuya M., Kurasawa K., Nagahama K., et al. Disrupted balance of angiogenic and antiangiogenic signalings in preeclampsia. J Pregnancy 2011, 2011:123717.
20. Heydarian M., McCaffrey T., Florea L., et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 2009, 30(3):250-255.
21. Nagamatsu T., Fujii T., Kusumi M., et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 2004, 145(11):4838-4845.
22. Gu Y., Lewis D.F., Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008, 93(1):260-266.
23. Schoofs K., Grittner U., Engels T., et al. The importance of repeated measurements of the sFlt-1/PlGF ratio for the prediction of preeclampsia and intrauterine growth restriction. J Perinat Med 2014, 42:61-68.
24. Villa P.M., Hämäläinen E., Mäki A., et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth 2013, 13:110.
25. Kusanovic J.P., Romero R., Chaiworapongsa T., et al. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med 2009, 22(11):1021-1038.
26. Heydarian M., McCaffrey T., Florea L., et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 2009, 30(3):250-255.
27. Rajakumar A., Michael H.M., Rajakumar P.A., et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 2005, 26(7):563-573.
28. Govender N., Naicker T., Rajakumar A., et al. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia. Eur J Obstet Gynecol Reprod Biol 2013, 170(1):100-105.
29. Perucci LO, Gomes KB, Freitas LG, et al. Soluble endoglin, transforming growth factor-Beta 1 and soluble tumor necrosis factor alpha receptors in different clinical manifestations of preeclampsia. PLoS One 22;9(5):e97632.
30. Hertig A., Lefevre G., Toumi K., et al. Soluble endoglin levels during normotensive and hypertensive pregnancies. Eur J Obstet Gynecol Reprod Biol 2008, 140(1):138-140.
31. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003, 278(15):12605-12608.
32. Rana S., Karumanchi S.A., Levine R.J., et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 2007, 50(1):137-142.
33. Yelumalai S., Muniandy S., Omar S.Z., et al. Pregnancy- induced hipertension and preeclampsia: levels of angiogenic factors in Malaysian women. J Clin Biochem Nutr 2010, 47:191-197.
34. Mimura K., Tomimatsu T., Sharentuya N., et al. Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia. Am J Obstet Gynecol 2010, 202(5):464.e1-6.
35. Stepan H., Herraiz I., Schlembach D., et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015, 45:241-246.
36. Gilbert J.S., Verzwyvelt J., Colson D., et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placental ischemia-induced hypertension. Hypertension 2010, 55(2):380-385.
37. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. PNAS 201;108(4):1451-1455.
38. Bauer A.J., Banek C.T., Needham K., et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension 2013, 61(5):1103-1110.
39. Lam C., Lim K.H., Kang D.H., et al. Uric acid and preeclampsia. Semin Nephrol 2005, 25(1):56-60.
40. Spencer K., Cowans N.J., Chefetz I., et al. First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia. Ultrasound Obstet Gynecol 2007, 29(2):128-134.
41. Pozharny Y., Lambertini L., Clunie G., et al. Epigenetics in women's health care. Mt Sinai J Med 2010, 77(2):225-235.
42. Pineles B.L., Romero R., Montenegro D., et al. Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol 2007, 196(3). [261.e1-6.].
43. Barati M., Shahbazian N., Ahmadi L., et al. Diagnostic evaluation of uterine artery Doppler sonography for the prediction of adverse pregnancy outcomes. J Res Med Sci 2014, 19(6):515-519.
44. Uddin M.N., Allen S.R., Jones R.O., et al. Pathogenesis of pre-eclampsia: marinobufagenin and angiogenic imbalance as biomarkers of the syndrome. Transl Res 2012, 160(2):99-113.
45. Verdonk K., Visser W., Van Den Meiracker A.H. The renin-angiotensin-aldosterone system in pre-eclampsia: the delicate balance between good and bad. Clin Sci (Lond) 2014, 126(8):537-544.
46. Pinheiro Mde B., Junqueira D.R., Coelho F.F., et al. D-dimer in preeclampsia: systematic review and meta-analysis. Clin Chim Acta 2012, 24(414):166-170.
47. Boffa M.C., Valsecchi L., Fausto A., et al. Predictive value of plasma thrombomodulin in preeclampsia and gestational hypertension. Thromb Haemost 1998, 79(6):1092-1095.
48. Alpoim P.N., Gomes K.B., Godoi L.C., et al. ADAMTS13, FVIII, von Willebrand factor, ABO blood group assessment in preeclampsia. Clin Chim Acta 2011, 412(23-24):2162-2166.
49. Dusse L.M., Carvalho M.G., Cooper A.J., et al. Plasma factor VII: a potential marker of pre-eclampsia. Thromb Res 2011, 127(1):e15-e19.
50. Alpoim P.N., Godoi L.C., Freitas L.G., et al. Assessment of L-arginine asymmetric 1 dimethyl (ADMA) in early-onset and late-onset (severe) preeclampsia. Nitric Oxide 2013, 1(33):81-82.